was expected in our study, which may have resulted in a potential failure to detect a difference between both treatment groups. A larger study would be required to determine the proper role of cefprozil in the treatment of group A beta-hemolytic streptococcal infections.
Cefprozil, formerly known as BMY-28100, is a new semisynthetic 7-phenylglycyl cephalosporin developed for oral administration. Its broad-spectrum antibacterial activity and stability to hydrolysis by many P-lactamase enzymes, in combination with a more prolonged half-life when compared to other oral cephalosporins, has elicited interest in its potential clinical benefits for the treatment of various infections. In vitro data suggest that cefprozil is more active than either cefaclor or cephalexin against Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis (4, 5, 7, 10, 13) . The average half-life in blood of cefprozil is 1.2 h, in contrast to the serum half-life of cefaclor of 0.6 to 0.9 h (2). Phase I studies have demonstrated that the incidence and types of side effects observed with cefprozil are similar to those reported with other oral cephalosporins (1) .
Recent reports have documented high failure rates in some patients treated with penicillin for group A streptococcal pharyngitis (3, 8, 14) . The inability to eradicate group A streptococci may be due to a residual or recurrent infection; the persistence of a carrier state may be due to the presence of ,B-lactamase-producing aerobic and anaerobic bacteria in the oropharynx (3, 9) . Clinical trials with ,B-lactamase stable compounds and anti-anaerobe agents have been found to be more effective in eradicating the carrier state and preventing recurrent infection (3, 9, 14) . Cefprozil, with its stability to hydrolysis by plasmid-mediated P-lactamase enzymes, may be a good drug to evaluate under this assumption (4, 7) . Its once-a-day dosing may also result in increased compliance with the treatment regimen.
* Corresponding author.
The purpose of this study was to compare the efficacy and safety of cefprozil administered once a day with that of cefaclor, in the management of group A beta-hemolytic streptococcal (GABHS) pharyngitis. , urine analysis (with microscopic examination), prothrombin and partial thromboplastin times, anti-streptolysin 0 titer, and pharyngotonsillar area culture. The posterior pharyngeal wall and tonsils, if present, were swabbed vigorously. Swabs were cultured on blood agar plates soon after collection. A positive culture was defined as 10 or more CFU of GABHS on a blood agar plate. Patients were reevaluated (clinical and bacteriologic assessments) 3 to 5 days into therapy, between 2 and 6 days after therapy, and between 10 and 20 days after therapy.
MATERIALS AND METHODS

Patients
Patients were randomized to receive either 500 mg of cefprozil (BMY-28100, Bristol-Myers Squibb Company) orally once daily or 250 mg of cefaclor (Ceclor, Eli Lilly & Co.) three times a day (2:1 randomization). Randomization was performed by research assistants, utilizing a computergenerated randomization list provided by the sponsor. Both drug regimens were administered for a total of 10 days. To document compliance with the study, the patient was asked to return all unused capsules at the completion of the study. Patients needed to receive the study drug for at least 9 consecutive days in order to be eligible for evaluation of efficacy. No other antimicrobial therapy was given concomitantly with the study drug. Assessment of efficacy was performed only on patients with a duration of symptoms of less than or equal to 4 days.
Clinical responses were classified as follows: satisfactory, resolution or improvement of all pretreatment signs and symptoms without the appearance of any new signs or symptoms at the time of the posttreatment evaluation; unsatisfactory, pretreatment signs or symptoms unchanged or worsened or all pretreatment signs symptoms resolved but new symptoms appearing at the time of posttreatment evaluation.
Bacteriologic responses were categorized as follows: eradicated, all cultures negative after the completion of treatment and at the time of the posttreatment cultures; persisted, a positive culture with GABHS taken 2 to 6 days after completion of therapy; recurrence, a positive culture at 7 to 20 days following a negative at 2 to 6 days, after completion of treatment.
GABHS were identified by bacitracin disk screening followed by slide agglutination with specific antiserum (PathoDx, Los Angeles, Calif.). All bacterial isolates were tested for antimicrobial susceptibility, by using disks impregnated with 30 jig of cefprozil or cephalothin, by the KirbyBauer method of disk diffusion on Mueller-Hinton agar (11) . Organisms were considered resistant if the zones of inhibition were less than 14 mm; they were considered susceptible if the zones of inhibition were >18 mm.
Patients were disenrolled from the study if they met any of the following criteria: no GABHS isolated in pretreatment culture; in vitro susceptibility testing indicating resistance of the pathogen to either cefprozil or cefaclor; poor clinical response after 72 h of therapy; or occurrence of a serious or alarming adverse reaction related to the study drug.
The study drugs were compared for their overall clinical and bacteriological response rates and incidence and severity of adverse reactions. Statistical analysis was performed by using Fisher's exact test. A P value equal to or less than 0.05 was considered to be significant. 
RESULTS
Ninety-four patients were enrolled in this clinical trial. Sixteen patients were subsequently disenrolled because they did not meet criteria for eligibility to be evaluable (12 because of no pathogen isolated, 3 because of lack of compliance with study protocol, 1 because of abnormal pretreatment laboratory test values). A total of 78 patients (50 treated with cefprozil, 28 treated with cefaclor) were eligible for safety evaluation. Only those patients who were prematurely disenrolled because of adverse events or those who received drug for at least 9 days were included in the statistical evaluation of safety, although no adverse events were observed among the other patients. Four patients required discontinuation of study drugs because of adverse effects (3 for cefprozil, 1 for cefaclor). Five patients (three with non-GABHS pharyngeal pathogens [group G or C beta-hemolytic streptococci], two with GABHS isolates not tested for antimicrobial susceptibility) not eligible for efficacy analysis, who completed 10 days of treatment, were included in the safety analysis. Seventeen patients with symptoms of disease of more than a 4-day duration were excluded from the efficacy analysis; they were included in the analysis for safety. Fifty-three patients were eligible for evaluation for efficacy.
Both treatment groups were comparable in sex distribution, underlying illnesses, and type and severity of signs and symptoms of pharyngitis-tonsillitis. The mean ages for patient groups were as follows: cefprozil, 33.6 years (range, 14 to 66 years; median, 31 years); cefaclor, 31.2 years (range, 13 to 50 years; median, 31 years), P = 0.41. The mean durations of signs and symptoms of disease (in patients eligible for efficacy analysis) for cefprozil and cefaclor were 2.95 and 2.52 days, respectively (median, 3 days for each group).
The clinical and bacteriological responses are summarized in Table 1 . The percentages of patients responding favorably, either with clinical improvement or resolution of signs and symptoms of disease, were equal for both treatment groups. None of the patients who had unsatisfactory clinical responses to a study drug had a concomitant positive pharyngeal or tonsillar culture. GABHS were eradicated at a similar percentage in both treatment groups. All patients with bacteriological persistence or recurrence were asymptomatic. All patients evaluable for efficacy analysis took the study drug for 10 days; this was confirmed by a pill count.
The incidence of adverse reactions is summarized in Table  2 . These were more commonly observed in the cefproziltreated patients. Leukopenia (defined as a leukocyte count <5,000/mm3) and nausea were more common in the cefprozil-treated group. Vaginal yeast infection, erythema no- dosum, thrombocytosis (>450,000/mm3), prolonged partial thromboplastin time (60 s) were reported once each in the cefprozil-treated group. All these adverse events were thought to be related to the study drug, and all resolved after discontinuation of the study drug. One patient treated with cefaclor suffered from serum sickness 2 days after completing therapy. Three patients were discontinued from the study because of their adverse reactions. Nausea was the cause for this discontinuation from study; all of these episodes occurred in cefprozil-treated patients. Nausea resolved after administration of cefprozil was discontinued. Although these adverse events were more common in the cefprozil-treated group, they did not reach statistical significance (nausea, P = 0.21; leukopenia, P = 0.14). (8, 14) . P-lactamase-producing microflora such as S. aureus, H. influenzae, H. parainfluenzae, M. catarrhalis, and anaerobic bacteria in the oropharynx have been suggested as possible causes of such treatment failures (3, 9) . Results of previous attempts to decrease GABHS persistence by treating patients with oral narrow-spectrum cephalosporins have been inconsistent. However, trials with cefaclor have demonstrated statistically significant decreased failure rates when compared with penicillin (12, 14) . Since in vitro data indicate that susceptibility of common pediatric pathogens to cefprozil is superior to that of cefaclor (4, 5, 9) , cefprozil may be of benefit in the management of these infections. In addition, an antimicrobial agent requiring less-frequent administration may increase compliance (6) . 
